ClinicalTrials.Veeva

Menu
C

Centro Respiratorio Quilmes | Buenos Aires, Argentina

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Astegolimab
Albuterol Sulfate
Fluticasone Propionate
Lebrikizumab
CHF5993
MTPS9579A
AP01
Povorcitinib
BAY1817080
Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 17 total trials

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Active, not recruiting
Pulmonary Fibrosis Secondary to Systemic Sclerosis
Pulmonary Fibrosis
Drug: AP01
Other: Placebo

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Active, not recruiting
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo
Status recently updated

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic m...

Active, not recruiting
Asthma
Drug: TEV-56248
Drug: Albuterol sulfate
Locations recently updated

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokin...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: PIPE-791 Dose B
Drug: Placebo

This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. W...

Enrolling
Asthma
Drug: CHF5993 pMDI with HFA-134a
Drug: CHF5993 pMDI with HFA-152a

Trial sponsors

Roche logo
Genentech logo
T
A
Bayer logo
Chiesi logo
C
Daiichi Sankyo logo
Incyte logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems